4-1BB Bioassay

Creative Biolabs is a leading global service provider focused on therapeutic antibody development and antibody functional characterization services. Here, we will introduce our 4-1BB Bioassay for measuring the potency and the mechanism of action (MOA) of monoclonal antibodies (mAbs) targeting the costimulatory 4-1BB.

Introduction to 4-1BB

4-1BB, also known as CD137 or TNF receptor superfamily 9 (TNFRSF9), is a costimulatory molecule and type I transmembrane protein which is mainly expressed on a range of cells, including T cells, B cells, and natural killer (NK) cells. 4-1BB plays an important role in regulating T cell activation, cell proliferation as well as cell differentiation. The ligand for 4-1BB (4-1BBL) is expressed predominantly by antigen-presenting cells (APCs). 4-1BB/4-1BBL interaction is involved in alloimmune responses. Studies have demonstrated that agonistic 4-1BB mAbs can enhance antitumor effects against a series of tumors. 4-1BB mAbs have been proved to be useful in enhancing the generation and persistence of antitumor T cells by activating CD8⁺ T cells both in vitro and in vivo.

Fig. 1 The function of 4-1BB signaling in multiple types of cells.¹

4-1BB Bioassay Provided by Creative Biolabs

4-1BB is one of the immune checkpoints that have proven to be potential immunotherapy targets for tumor treatment. Creative Biolabs offers 4-1BB Bioassay based on bioluminescent methods to test the potency and investigate the MOA of your antibody candidates targeting 4-1BB. This assay has overcome some of the limitations of traditional methods, such as complex assay protocols, unqualified assay reagents, and heterogeneous source of donor primary cells. Moreover, we have developed reporter gene assays targeting other immune checkpoints, including both inhibitory and stimulatory. With accumulated experience in this field, Creative Biolabs can offer high-quality services at reasonable prices to our global clients. Our services are characterized by:

• Excellent expert team to offer real-time technical guidance
• Advanced assay platform to promote the data output
• Timely data feedback to facilitate the process of your project

Popular Products

Creative Biolabs provides a comprehensive range of 4-1BB bioassay kits designed for the characterization of 4-1BB activity and the development of innovative antibodies. Moreover, we also offer 4-1BB cell lines for global customers. The products include but not are limited to the following:

Support Data

Background: CD137 (4-1BB; TNFSR9) is an activation-induced receptor that enhances the survival, proliferation, and effector functions of antigen-primed T cells through costimulation. This mechanism is being leveraged for cancer immunotherapy using agonist agents that bind and crosslink CD137 to trigger intracellular signaling.

Summary: This study investigates the differential impact of CD137-costimulation provided in cis versus trans relative to antigen presentation. The findings reveal that cis-costimulation significantly enhances T cell functionality, leading to robust NF-κB signaling and transcriptomic changes that promote proliferation and DNA repair. Consequently, CD8+ T cells costimulated via CD137 in cis demonstrate superior efficiency and performance in vivo.

Fig.2 Cis CD137 co-stimulation more effectively triggers NF-κB activation.²

Creative Biolabs is recognized as a world-leading company for providing the most diverse portfolio of antibody function analysis solutions for worldwide customers. We have accumulated extensive experience from the accomplished projects and are confident in meeting any special need of your research. For more detailed information, please feel free to contact us or directly sent us an inquiry.

References

1. Kim, Alyssa Min Jung, et al. "4-1BB: A promising target for cancer immunotherapy." Frontiers in Oncology 12 (2022): 968360.
   Distributed under Open Access License CC BY 4.0, without modification.
2. Otano, Itziar, et al. "CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation." Nature Communications 12.1 (2021): 7296.
   Distributed under Open Access License CC BY 4.0. The original image was modified by extracting and using parts a, b, and c, and the title was changed to "Cis CD137 co-stimulation more effectively triggers NF-κB activation".

For Research Use Only.